Pfizer, Inc. (NYSE:PFE) has been assigned a $38.00 price target by equities research analysts at Barclays PLC in a research note issued on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Barclays PLC’s price objective would suggest a potential upside of 4.40% from the stock’s previous close.
A number of other equities research analysts also recently weighed in on PFE. BMO Capital Markets set a $37.00 price target on Pfizer and gave the company a “buy” rating in a research report on Tuesday. Berenberg Bank restated a “hold” rating and set a $36.00 price target (down previously from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Tuesday, October 3rd. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Finally, BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $38.21.
Shares of Pfizer (NYSE PFE) opened at 36.40 on Wednesday. Pfizer has a 12 month low of $29.83 and a 12 month high of $36.51. The company has a market cap of $216.48 billion, a price-to-earnings ratio of 26.63 and a beta of 1.00. The company’s 50-day moving average price is $34.92 and its 200-day moving average price is $33.71.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter last year, the business posted $0.64 earnings per share. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. Analysts anticipate that Pfizer will post $2.56 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This report was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://stocknewstimes.com/2017/10/11/barclays-plc-analysts-give-pfizer-inc-pfe-a-38-00-price-target.html.
In related news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares in the company, valued at $5,097,715. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock worth $15,813,961 over the last three months. 0.06% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Altfest L J & Co. Inc. grew its stake in shares of Pfizer by 67.0% in the second quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock worth $3,603,000 after purchasing an additional 43,024 shares during the last quarter. Sphera Funds Management LTD. bought a new stake in shares of Pfizer in the first quarter worth about $13,342,000. Searle & CO. grew its stake in shares of Pfizer by 92.7% in the first quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock worth $2,739,000 after purchasing an additional 38,500 shares during the last quarter. Insight 2811 Inc. grew its stake in shares of Pfizer by 3.7% in the first quarter. Insight 2811 Inc. now owns 9,324 shares of the biopharmaceutical company’s stock worth $319,000 after purchasing an additional 329 shares during the last quarter. Finally, Washington Trust Bank grew its stake in shares of Pfizer by 0.7% in the second quarter. Washington Trust Bank now owns 51,052 shares of the biopharmaceutical company’s stock worth $1,715,000 after purchasing an additional 377 shares during the last quarter. 68.99% of the stock is currently owned by institutional investors.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.